In Brief: Sanofi Diagnostics Pasteur
This article was originally published in The Gray Sheet
Executive SummarySanofi Diagnostics Pasteur: Releases myoglobin assay for use on its Access automated immunoassay system. The test is a "paramagnetic-particle, chemiluminescent immunoassay for the quantitative determination of myoglobin levels in human serum or plasma EDTA," Sanofi says. The myoglobin test is the second of three cardiac assays planned for inclusion on the Access. Sanofi launched its Access CK-MB test earlier this fall ("The Gray Sheet" Oct. 16, In Brief). The firm is planning to launch a troponin-I test in 1996...
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.